Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

NCT07323095 is registered in ClinicalTrials.gov with Atom Therapeutics Co., Ltd as lead sponsor.

NCT NCT07323095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07323095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
Lead sponsor
Atom Therapeutics Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
January 31, 2028
Enrollment
80 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease